![Foto de Rocío](/img/nophoto.png)
Rocío
Aller de la Fuente
Publications by the researcher in collaboration with Rocío Aller de la Fuente (9)
2024
-
Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)
Gastroenterologia y Hepatologia
-
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Hepatology, Vol. 79, Núm. 1, pp. 135-148
-
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis
Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597
2022
-
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Hepatology, Vol. 76, Núm. 4, pp. 1121-1134
2021
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
2020
-
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
2018
-
The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity
Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270